DDA recalls Nepali antibiotic over quality concerns
Summary
Nepal's Department of Drug Administration recalled the third-generation antibiotic Levoflox-500 due to substandard quality, highlighting delays in quality testing and monitoring challenges.
Key Points
- The Department of Drug Administration (DDA) recalled Levoflox-500 batch BB24001 manufactured by Magnus Pharma due to failing quality standards in dissolution tests.
- The recalled batch was collected almost a year ago but the quality report took nearly a year to be released, raising concerns about the medicine's circulation.
- DDA officials acknowledge understaffing and challenges in monitoring pharmacies and ensuring complete drug recalls across Nepal.
- Experts warn that delays in detecting and recalling substandard medicines pose serious health risks, including worsening conditions and potential fatalities.
